February 19, 2020
NIAID scientists working with investigators from the University of Texas at Austin identified the atomic structure of an important protein on the surface of the novel coronavirus (SARS-CoV-2, formerly called 2019-nCoV). The findings appear in the peer-reviewed journal Science.
October 25, 2019
In recent months, an uptick in cases of eastern equine encephalitis virus (EEEV) infections in Connecticut, Massachusetts, Michigan, and elsewhere in the United States has raised alarm. At NIAID, researchers are working to develop both vaccines and therapeutics to fight this rare but deadly virus.
Supporting the Next Generation of Biomedical Researchers: New Information Available on NIAID Training Opportunities
April 02, 2019
NIAID has many opportunities available through training programs, whether you are a high school student or an early-career scientist or anything in between. Trainees conduct research focused on infectious, immunologic, and allergic diseases in NIAID laboratories, providing a unique scientific research training environment in basic, translational, and clinical research.
October 25, 2018
At this week's HIV Research for Prevention (HIV R4P) conference in Madrid, scientists have reported progress in numerous areas of HIV prevention research. NIAID-supported scientists highlighted the need to expand HIV prevention and treatment services among populations greatly affected by HIV, described early findings from a study assessing the safety of a vaginal ring containing both an anti-HIV drug and a birth-control agent, and reported the added benefits of an intervention designed to facilitate treatment for HIV and injection drug use.
October 23, 2018
A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D. Yesterday, Dr. Fauci delivered a plenary lecture at the opening session of the HIV Research for Prevention (HIV R4P) conference, which is taking place this week in Madrid.
June 25, 2018
The Democratic Republic of the Congo (DRC) is experiencing an outbreak of Ebola virus disease. As the U.S. government’s lead agency on biomedical infectious disease research, NIAID is providing several layers of support to the DRC and World Health Organization, which are leading a global, multi-sectoral response to the outbreak.
May 11, 2018
The Partnership for Public Service recently named NIAID scientists Barney S. Graham, M.D., Ph.D., and Theodore C. Pierson, Ph.D., as Samuel J. Heyman Service to America Medal finalists for their work in developing a candidate vaccine against Zika virus.
March 22, 2018
Most people living with HIV have a single genetic strain of the virus, but in certain cases, a person can acquire a second strain of HIV—a condition known as HIV superinfection. In a new study published online today in the Journal of Infectious Diseases, NIAID researchers and scientists at the Uganda Virus Research Institute describe a case of HIV superinfection they were able to identify with unique precision.
March 08, 2018
Our coverage from the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston wrapped up yesterday with two interviews with Federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
February 20, 2018
NIAID scientists have demonstrated that a slight change to a powerful, naturally occurring HIV antibody helps it last longer in the human body while counteracting the virus just as well in the laboratory. These characteristics could reduce the cost and increase the convenience of giving people antibodies for HIV prevention because fewer doses of an antibody could achieve the same protective effect.
Critical Collaboration Agreements for Ebola Vaccine Candidates Earn NIAID an Excellence in Technology Transfer Award
November 13, 2017
In 2014, as the Ebola outbreak escalated, NIAID collaborated with pharmaceutical company GlaxoSmithKline on NIAID-planned clinical trials to test Ebola vaccine candidates. Their collaboration exemplifies the flexibility and creativity of the NIAID Technology Transfer and Intellectual Property Office, who developed unique and expedited agreements to facilitate the development of an Ebola vaccine.